Benitec Biopharma Inc (BNTC) financials
Benitec Biopharma revenue and earnings by year
Benitec Biopharma's revenue was $75,000 in the fiscal year to June 30, 2023, up 2.7% from the year before. Net income was -$19.6 million, -26082.7% of revenue. Since the fiscal year to June 30, 2017, revenue has shrunk 53.6% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 12 | 3 | 8 |
| Revenue growth | 2.7% | 23.7% | -42.2% | -99.2% | 292.0% | -58.8% | — |
| Operating income | -19 | -18 | -14 | -8 | 3 | -8 | -4 |
| Operating margin | -25441.3% | -24457.5% | -23044.1% | -8118.6% | 21.2% | -264.2% | -52.4% |
| Net income | -20 | -18 | -14 | -8 | 3 | -8 | -4 |
| Net margin | -26082.7% | -24942.5% | -23528.8% | -8111.8% | 21.4% | -260.7% | -52.5% |
| Diluted EPS | -$14.12 | -$37.88 | — | — | — | — | — |
| Free cash flow | -18 | -16 | -13 | -8 | 4 | -7 | -6 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open BNTC in Markets.
See also: BNTC returns
No forecast, no recommendation. This page describes Benitec Biopharma Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.